Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) CEO Dr Vladislav Sandler and non-executive director Peter Redmond talked with Proactive's Stephen Gunnion about key developments within the company.
Redmond explained the recent 400-to-1 share consolidation, intended to attract serious institutional investors.
Sandler shared insights from his attendance at the Chemical and Biological Defense Conference in Florida and the American Society of Hematology conference in San Diego. He emphasised growing interest in the company’s CAR-T program for treating acute myeloid leukaemia (AML), which is progressing towards its first clinical trials.
Sandler and Redmond also spoke about the significant breakthrough in the company’s CBR (Chimeric Bait Receptor) program, emphasising its potential impact alongside CAR-T development.
Hemogenyx Pharmaceuticals remains focused on delivering innovative treatments, expanding into pediatric CAR-T applications, and advancing its clinical programs. As Sandler stated, 'We may have a chance to partner with entities to develop one-day manufacturing, reaching the next level of CAR-T delivery.
